Last reviewed · How we verify

NCT04906538

Objective Results of Anterior Cruciate Ligament Reconstruction With and Without Internal Suture Augmentation Technique

Completed Phase 2, PHASE3 Last updated 2 June 2021
What this trial tests

Phase 2, PHASE3 trial testing all- inside anterior cruciate ligament reconstruction in Anterior Cruciate Ligament Injuries in 38 participants. Completed in 1 April 2021.

Timeline
1 September 2018
Primary endpoint
1 April 2021
1 April 2021

Quick facts

Lead sponsorAin Shams University
PhasePhase 2, PHASE3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment38
Start date1 September 2018
Primary completion1 April 2021
Estimated completion1 April 2021
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 20 to 35, any sex, with Anterior Cruciate Ligament Injuries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is (1) To report, compare and corelate the patient reported outcomes (PRO) (IKDC score, Lysholm Score) and range of motion (ROM) among patients following hamstring autograft ACLR with and without independent suture tape reinforcement against objective laxity test using Lachmeter. (2) Rate of complications and reoperation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Anterior Cruciate Ligament Injuries

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04906538.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing